PBB-8-IN

 

PBB-8-IN is a long acting FVIII, which Pro Bono Bio intends to trial in HA patients with inhibitors. About 25-30% of severe HA patients develop inhibitors to FVIII replacement therapy, rendering such therapy ineffective. These patients either take on-demand bypass therapies losing the benefits of prophylactic treatment, or undergo costly and unpleasant Immune Tolerance Induction therapy.

Pro Bono Bio intends to begin a Ph II clinical trial in early 2017.